quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:49:09·64d
INSIDERFiling
Exelixis Inc. logo

Director Eckhardt Sue Gail sold $168,854 worth of shares (3,856 units at $43.79), decreasing direct ownership by 18% to 17,524 units (SEC Form 4)

EXEL· Exelixis Inc.
Health Care
Original source

Companies

  • EXEL
    Exelixis Inc.
    Health Care

Recent analyst ratings

  • Jan 8UpdateMorgan Stanley$48.00
  • Jan 5UpdateBofA Securities$41.00
  • Nov 18UpdateWolfe Research-
  • Nov 3UpdateGuggenheim-
  • Oct 21UpdateLeerink Partners$48.00
  • Sep 19UpdateBarclays$40.00

Related

  • PR2d
    Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
  • SEC6d
    SEC Form DEFA14A filed by Exelixis Inc.
  • SEC8d
    SEC Form DEFA14A filed by Exelixis Inc.
  • SEC8d
    SEC Form DEF 14A filed by Exelixis Inc.
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Exelixis Inc.
  • INSIDER52d
    EVP, Research and Development Aftab Dana was granted 52,018 shares, increasing direct ownership by 8% to 668,124 units (SEC Form 4)
  • INSIDER52d
    SVP and General Counsel Hefti Brenda was granted 23,119 shares, increasing direct ownership by 24% to 119,631 units (SEC Form 4)
  • INSIDER52d
    EVP and CFO Senner Christopher J. was granted 52,018 shares, increasing direct ownership by 5% to 1,028,110 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022